ERBB2 and breast cancer: Later on, considerable progress has been made as several categories of HER2-targeting agents, including additional mAbs, signal transduction inhibitors, novel tyrosine kinase inhibitors (TKIs) which showed excellent efficacy in both early-stage and metastatic HER2-positive breast cancer.